Considerations for the development of Zika virus vaccines

Vaccine

Volumn 34, Issue 33, 2016, Pages 3711-3712

  Martins, K A O ^a,b   Dye, J M ^a   Bavari, S ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Ke'Aki Technologies LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIKA VIRUS VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS VACCINE;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIGENICITY; CROSS REACTION; DISEASE ASSOCIATION; FETUS DISEASE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOGENICITY; MICROCEPHALY; NONHUMAN; NOTE; PRIORITY JOURNAL; ZIKA FEVER; ZIKA VIRUS; FEMALE; IMMUNOLOGY; MEDICAL RESEARCH; PREGNANCY; PREGNANCY COMPLICATION; VACCINE IMMUNOGENICITY; VIROLOGY;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BIOMEDICAL RESEARCH; FEMALE; HUMANS; IMMUNOGENICITY, VACCINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIRAL VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 84990946923     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.06.012     Document Type: Note

References (13)

1. [1] Dyer, O., Zika vaccine could be in production by year's end, says maker. BMJ, 352, 2016, i630.
2. [2] Lanciotti, R.S., Kosoy, O.L., Laven, J.J., et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis 14:8 (2008), 1232–1239.
3. [3] Francis, T. Jr., Influenza: the new acquayantance. Ann Intern Med 39:2 (1953), 203–221.
4. [4] Halstead, S.B., Rojanasuphot, S., Sangkawibha, N., Original antigenic sin in dengue. Am J Trop Med Hyg 32:1 (1983), 154–156.
5. [5] Mongkolsapaya, J., Dejnirattisai, W., Xu, X.N., et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9:7 (2003), 921–927.
6. [6] Mizumoto, K., Ejima, K., Yamamoto, T., Nishiura, H., On the risk of severe dengue during secondary infection: a systematic review coupled with mathematical modeling. J Vector Borne Dis 51:3 (2014), 153–164.
7. [7] Flipse, J., Smit, J.M., The complexity of a dengue vaccine: a review of the human antibody response. PLoS Neglected Trop Dis, 9(6), 2015, e0003749.
8. [8] Beck, C., Jimenez-Clavero, M.A., Leblond, A., et al. Flaviviruses in Europe: complex circulation patterns and their consequences for the diagnosis and control of West Nile disease. Int J Environ Res Public Health 10:11 (2013), 6049–6083.
9. [9] Paul, L.M., Carlin, E.R., Jenkins, M.M., et al. Dengue virus antibodies enhance zika virus infection. bioRxiv, 2016.
10. [10] Izurieta, R.O., Macaluso, M., Watts, D.M., et al. Anamnestic immune response to dengue and decreased severity of yellow fever. J Glob Infect Dis 1:2 (2009), 111–116.
11. [11] Johnson, B.W., Kosoy, O., Martin, D.A., et al. West Nile virus infection and serologic response among persons previously vaccinated against yellow fever and Japanese encephalitis viruses. Vector Borne Zoonotic Dis 5:2 (2005), 137–145.
12. [12] Martines, R.B., Bhatnagar, J., Keating, M.K., et al. Notes from the field: evidence of Zika virus infection in brain and placental tissues from two congenitally infected newborns and two fetal losses – Brazil, 2015. MMWR Morb Mortal Wkly Rep 65:6 (2016), 159–160.
13. [13] Hills, S.L., Russell, K., Hennessey, M., et al. Transmission of Zika virus through sexual contact with travelers to areas of ongoing transmission – continental United States, 2016. MMWR Morb Mortal Wkly Rep 65:8 (2016), 215–216.